Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06218914 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Colorectal Carcinoma
Pancreatic Ductal Adenocarcinoma
Endometrial Cancer
Solid Tumor, Adult
KRAS G12D

Interventions

BIOLOGICAL: NT-112: Autologous, engineered T Cells targeting KRAS G12D
BIOLOGICAL: AZD0240: Autologous, engineered T Cells targeting KRAS G12D

Sponsor

AstraZeneca